Shanghai Henlius Biotech (HKG:2696) recorded a rise in attributable profit in the first half of 2025 to 390.1 million yuan from 386.3 million yuan in the year-ago period, a Monday Hong Kong bourse filing said.
The pharmaceutical company's earnings per share were 0.72 yuan in the half year, up from 0.71 yuan in the corresponding period of the last year.
Revenue in the six months rose 2.7% to 2.82 billion yuan from 2.75 billion yuan a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.